ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS

Antimicrobial Susceptibility Testing Market, By Product Type (Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, and Consumables), By Application (Antibacterial, Antifungal, Anti-parasitic, and Antiviral), By Method (Disk Diffusion, Rapid Automated AST, Broth Dilution, Gradient Diffusion, and Genotypic Methods), By End User (Hospitals, Pathology/Diagnostic Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, and Contract Research Organizations), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In May 2022, Qualigen Therapeutics, Inc., a biotechnology company, announced that NanoSynex Ltd, a company with whom Qualigen recently entered into definitive agreements to acquire a majority stake, featured at BioMed Israel. Innovative Technology by NanoSynex focuses to accelerate antimicrobial susceptibility test results times by six-fold.
In April 2022, Copan Diagnostics Inc., a healthcare company, demonstrated its range of fully automated solutions for identification and antimicrobial susceptibility testing (AST) in clinical microbiology at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022). COPAN demonstrated the Food and Drug Administration-cleared Colibri, a fully automated specimen workup instrument designed to prepare MALDI-TOF ID targets and create bacterial suspensions for AST.
In July 2020, Cepheid, a subsidiary of Danaher, launched a novel rapid molecular test for TB which can detect multi-drug resistance to first-line and second-line drugs simultaneously. The profiling can be achieved in less than 90 minutes. This will drive the antimicrobial testing market in the coming years.